WHAT THE HUMAN DATA SAY
Evidence before enthusiasm.
Small pilot studies suggest biological activity in humans, but effective targets, agents, timing, long-term risks and meaningful clinical outcomes remain unsettled.
This grade reflects clinically meaningful human evidence for the use described here. It is not a score for popularity, mechanism, animal lifespan results or the number of products already being sold.
HOW IT FITS
A practical role—without pretending it is universal.
Follow the field through registered trials. Do not copy high-dose fisetin or dasatinib-plus-quercetin protocols from online anecdotes.
TRACK WHAT MATTERS
Know whether it is creating value.
Clinical-trial outcomes
Validated senescence biomarkers as they emerge
Adverse-event and long-term safety data
SAFETY & BOUNDARIES
What should make you pause.
- Dasatinib is a prescription cancer drug with serious risks.
- High-dose flavonoids can interact with medications and are not proven senolytics in humans.
- Clearing the wrong cells or using the wrong timing could be harmful.
BOOK CONNECTIONS
Where this idea enters the longevity conversation.
Book inclusion explains why the idea is culturally important; the evidence grade above determines how strongly The Modern Bio treats the claim.